Business Context and Reporting Period
This Form 8-K filing by IRADIMED CORP (IRMD) was submitted on July 8, 2021. The report discloses a significant executive appointment and the terms of a new employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance.
Material Changes
The primary material change reported is the appointment of Chris Scott as Chief Financial and Operating Officer, effective July 8, 2021. Mr. Scott, who previously served as Chief Financial Officer since December 2013, has expanded his role to include oversight of operations functions including customer service, supply chain, manufacturing, regulatory, and quality affairs.
Management Commentary and Compensation Details
The filing details the terms of Mr. Scott's Amended and Restated Employment Agreement:
- Base Salary: $360,000 per year.
- Annual Cash Bonus: Targeted at 60% of base salary.
- Equity Awards: Targeted annual value of $400,000, subject to performance goals.
- Immediate Grant: Restricted stock units (RSUs) valued at $150,000, vesting in four equal annual installments.
- Severance Provisions:
- Termination without cause or resignation for good reason: 12 months of base salary.
- Change of control followed by resignation for good reason: 18 months of base salary.
- Restrictions: The agreement includes non-solicitation, non-compete, and confidentiality provisions.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Employment Agreement filed as Exhibit 10.1.
- Confirm the vesting schedule and performance metrics for the $400,000 targeted equity awards.
- Review the specific definitions of "good reason" and "change of control" within the agreement to understand severance triggers.
- Check subsequent filings for any impact of this role expansion on the company's operational strategy.